The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 02, 2020

Filed:

May. 06, 2015
Applicant:

Berg Llc, Nashville, TN (US);

Inventors:

Niven Rajin Narain, Cambridge, MA (US);

Indushekhar Persaud, Homestead, FL (US);

John Patrick McCook, Frisco, TX (US);

Assignee:

Berg LLC, Framingham, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/122 (2006.01); C12Q 1/6869 (2018.01); C12Q 1/6809 (2018.01); A61K 9/127 (2006.01); A61K 9/02 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/12 (2006.01);
U.S. Cl.
CPC ...
A61K 31/122 (2013.01); A61K 9/127 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 9/0075 (2013.01); A61K 9/02 (2013.01); A61K 9/06 (2013.01); A61K 9/12 (2013.01);
Abstract

The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q1O or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q1O or its metabolites thereof in addition to but not limited to mevalonic acid and oleic acid to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q1O in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis.


Find Patent Forward Citations

Loading…